Search
Genelux Corp
GNLXAdd to Watchlist
2.965USD
+0.005+0.17%
Close 07-23 16:00（ET）Quotes delayed by 15 min
131.67MMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-07-23The current earnings forecast score of Genelux Corp is 8.00, ranking 168 out of 386 in the Biotechnology & Medical Research industry. The average price target is 18.00, with a high of 31.00 and a low of 10.00.
Analyst Rating
Based on
6
analysts
Buy
Current Rating
17.500
Target Price
+505.54%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
495
Total
6
Median
7
Average
Company name
Ratings
Analysts
Genelux Corp
GNLX
6
Beigene Ltd
ONC
28
argenx SE
ARGX
27
Ionis Pharmaceuticals Inc
IONS
26
IQVIA Holdings Inc
IQV
25
Insmed Inc
INSM
23
1
2
3
...
99
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Genelux Corp's price target?
Analysts forecast that Genelux Corp's price target is USD 18.00, with the highest forecast at USD 31.00 and the lowest forecast at USD 10.00.
How have Genelux CorpGNLX's recent earnings per share performed?
The market expectation was USD -0.20, while Genelux CorpGNLX's earnings per share (EPS) for the previous quarter was USD -0.24. EPS for the next quarter is expected at USD -0.20.
What is the analyst rating for Genelux Corp?
Based on the ratings of Genelux Corp's stock from 6 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.